$7.38 +0.33 (%) Synergy Pharmaceuticals Inc - NASDAQ

Aug. 27, 2015 | 04:00 PM

Partner Headlines

  1. Benzinga's Top Initiations

    Benzinga | Aug. 25, 2015 | 09:48AM EST
  2. Mid-Morning Market Update: Markets Open Lower; Time Warner Cable Profit Misses Expectations

    Benzinga | Jul. 30, 2015 | 10:30AM EST
  3. Synergy Pharmaceuticals Announces Positive Results in Second Phase 3 Trial of Plecanatide in Patients with CIC

    Benzinga | Jul. 30, 2015 | 06:07AM EST
  4. Paul Tudor Jones' Highest Performing Stocks

    GuruFocus | Jul. 13, 2015 | 16:16PM EST
  5. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following Announcement Of Positive BMN 111 Data; Jabil Circuit Shares Fall

    Benzinga | Jun. 18, 2015 | 15:32PM EST
  6. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius Health Shares Surge

    Benzinga | Jun. 18, 2015 | 13:31PM EST
  7. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings Beat Views

    Benzinga | Jun. 18, 2015 | 10:22AM EST
  8. Mid-Afternoon Market Update: DavidsTea Falls After Q1 Results; Synergy Pharmaceuticals Shares Spike Higher

    Benzinga | Jun. 17, 2015 | 14:55PM EST
  9. Mid-Day Market Update: Kythera Biopharmaceuticals Jumps On Acquisition News; La-Z-Boy Shares Slide

    Benzinga | Jun. 17, 2015 | 13:03PM EST
  10. Mid-Morning Market Update: Markets Rise; Allergan To Acquire Kythera Biopharmaceuticals For $2.1B

    Benzinga | Jun. 17, 2015 | 10:30AM EST
  11. Synergy Pharma Reports Positive Results from Phase 3 Trial of Plecanatide

    Benzinga | Jun. 17, 2015 | 06:03AM EST
  12. Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, ...

    GuruFocus | May. 18, 2015 | 17:20PM EST
  13. 1 Way To Search For The 'Next Big Thing' In Biotech

    Benzinga | Nov. 13, 2014 | 15:13PM EST
  14. Benzinga's Top #PreMarket Gainers

    Benzinga | Oct. 21, 2014 | 08:14AM EST
  15. US Stock Futures Down; Alcoa Earnings In Focus

    Benzinga | Jul. 8, 2014 | 07:35AM EST
  16. Small Pharmaceuticals Rallying Following FDA Report

    Benzinga | Jun. 9, 2014 | 12:49PM EST
  17. Benzinga's Top #PreMarket Gainers

    Benzinga | Apr. 30, 2014 | 08:57AM EST
  18. US Stock Futures Edge Higher Ahead Of Durable-Goods Orders Data

    Benzinga | Dec. 24, 2013 | 07:00AM EST
  19. Synergy Pharmaceuticals Closes Enrollment for Phase 2b Plecanatide Trial in Patients with IBS-C

    Benzinga | Dec. 24, 2013 | 06:07AM EST
  20. UPDATE: Aegis Capital Reiterates on Synergy Pharmaceuticals on Approaching Clinical Catalysts

    Benzinga | Nov. 13, 2013 | 10:56AM EST
  21. Synergy Pharmaceuticals Initiates Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

    Benzinga | Nov. 13, 2013 | 06:24AM EST
  22. US Stock Futures Down Ahead Of Jobless Claims Data

    Benzinga | Oct. 31, 2013 | 07:15AM EST
  23. Synergy Initiates Phase 2 Study of SP-333

    Benzinga | Oct. 31, 2013 | 06:04AM EST
  24. US Stock Futures Down; ADP Report In Focus

    Benzinga | Oct. 2, 2013 | 07:08AM EST
  25. Synergy Pharmaceuticals to Initiate Phase 2 Study of SP-333 for Opioid-Induced Constipation

    Benzinga | Oct. 2, 2013 | 06:00AM EST
  26. Synergy Pharmaceuticals to Spin-Off FV-100 Assets

    Benzinga | Aug. 8, 2013 | 20:25PM EST
  27. Synergy Pharmaceuticals, Inc. (SGYP) Chairman Gabriel Cerrone buys 5,000 Shares

    GuruFocus | Feb. 5, 2013 | 05:07AM EST
  28. Synergy Pharmaceuticals, Inc. (SGYP) Chairman Gabriel Cerrone buys 13,090 Shares

    GuruFocus | Feb. 4, 2013 | 07:07AM EST
  29. A Peek Into The Market Before The Trading Starts

    Benzinga | Jan. 28, 2013 | 00:19AM EST
  30. Synergy Pharmaceuticals Initiates Phase I Clinical trial of SP-333 for Treatment of IBD

    Benzinga | Jan. 27, 2013 | 22:48PM EST
  31. Synergy Pharmaceuticals Shareholders Approve Merger with Callisto Pharmaceuticals

    Benzinga | Jan. 14, 2013 | 23:12PM EST
  32. Stocks Soar on Fiscal Cliff Deal; Dow Climbs More Than 300 Points

    Benzinga | Jan. 2, 2013 | 09:34AM EST
  33. UPDATE: Canaccord Genuity Raises PT to $10 on Synergy Pharmaceuticals on Positive Plecanatide Data

    Benzinga | Jan. 2, 2013 | 06:12AM EST
  34. Benzinga's Top Pre-Market Gainers

    Benzinga | Jan. 2, 2013 | 02:19AM EST
  35. Synergy Reports Positive Phase IIb/III Trial Results for Plecanatide in Patients With Chronic Idiopathic Constipation

    Benzinga | Jan. 1, 2013 | 23:24PM EST
  36. Aegis Capital Reiterates Buy Rating, $25 PT on Synergy Pharmaceuticals

    Benzinga | Dec. 28, 2012 | 03:45AM EST
  37. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 28, 2012 | 00:23AM EST
  38. Synergy Pharmaceuticals Completes Phase I Trial of SP-333 to Treat Gastrointestinal Diseases

    Benzinga | Dec. 27, 2012 | 23:15PM EST
  39. A Peek Into The Market Before The Trading Starts

    Benzinga | Dec. 27, 2012 | 00:10AM EST
  40. Synergy Begins Phase IIb Trial of Plecanatide for IBS-C

    Benzinga | Dec. 26, 2012 | 23:10PM EST
  41. UPDATE: Canaccord Genuity Initiates Synergy Pharmaceuticals at Buy on Opportunities

    Benzinga | Nov. 7, 2012 | 00:03AM EST
  42. Synergy Pharma Files IND for Gastro Diseases Drug

    Benzinga | Sep. 12, 2012 | 02:42AM EST
  43. LyondellBasell Industries, BP Prudhoe Bay Royalty Included in Stocks Up on High Volume Thursday

    FoxBusiness | Aug. 30, 2012 | 06:33AM EST
  44. Synergy Pharma Buys FV-100 Drug from Bristol-Myers

    Benzinga | Aug. 23, 2012 | 10:46AM EST
  45. Low-Priced Small-Caps That Won't Stay That Way

    Benzinga | Jul. 19, 2012 | 08:28AM EST
  46. Synergy Pharmaceuticals Announces Exercise of Remainder of Over-Allotment Option by Aegis Capital Corp. Bringing Total Gross Proceeds to $51.75 Million

    Benzinga | Jun. 6, 2012 | 06:54AM EST
  47. Synergy Pharmaceuticals Announces Partial Exercise of Over-Allotment Option by Aegis Capital

    Benzinga | Jun. 5, 2012 | 10:18AM EST
  48. European Patent Office Upholds Synergy Pharmaceuticals' Grant of Claims to Plecanatide

    Benzinga | Jan. 3, 2012 | 23:52PM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!